Across TCGA pan-cancer cohorts, ALG3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ALG3 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ALG3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ALG3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, COAD, and THCA are the cancer types where ALG3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.184	0.730	.001	27	view →
COAD	DFS	Median	All	0.166	0.703	<.001	9	view →
THCA	OS	Median	All	0.342	0.955	<.001	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
UCEC	DFS	Median	All	0.953	0.630	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ALG3 tumor-vs-normal RNA expression · all ALG3 data types